natgillin/translations-raw huggingface dataset:
Data hos HCC-patienter med moderat nedsat leverfunktion (Child-Pugh B) er meget begrænsede, og der foreligger aktuelt ingen data vedrørende HCC-patienter med svært nedsat leverfunktion (ChildPugh C). 
Data in HCC patients with moderate hepatic impairment (Child-Pugh B) are very limited and there are currently no data available in HCC patients with severe hepatic impairment (Child-Pugh C).
Mediantiden til indtræden var 6,1 uger. 
The median time to onset was 6.1 weeks.
• ændrede blodprøveresultater for nyrefunktionen og nyresvigt 
• changes in blood test results for kidney function and kidney failure
Hypoalbuminæmi omfatter hypoalbuminæmi og et nedsat niveau af albumin i blodet. 
Hypoalbuminaemia includes hypoalbuminaemia and decreased blood albumin.
Forhøjet niveau af bilirubin i blodetj,‡ Hypoalbuminæmij,‡ 
Increased blood bilirubin j, ‡ Hypoalbuminaemiaj
De tilgængelige data tillader ikke en anbefaling af dosis hos HCC-patienter med svært nedsat nyrefunktion. 
The available data do not allow for a dosing recommendation for patients with HCC and severe renal impairment.
Fertile kvinder skal anvende meget sikker kontraception, mens de tager lenvatinib og i 1 måned efter behandlingsophør (se pkt. 
Women of childbearing potential must use highly effective contraception while taking lenvatinib and for one month after stopping treatment (see section 4.6).
Selvom virkningsmekanismen for hypertension ikke blev undersøgt direkte med lenvatinib, postuleres det, at den er medieret via hæmningen af VEGFR2 i vaskulære endotelceller. 
Although not studied directly with lenvatinib, the mechanism of action (MOA) for hypertension is postulated to be mediated by the inhibition of VEGFR2 in vascular endothelial cells.
Grad 3 eller værre reaktioner forekom hos 1,9 % af patienterne behandlet med lenvatinib. 
Grade 3 or greater reactions occurred in 1.9% of lenvatinib-treated patients.
Tabel 1 Dosismodifikationer fra den anbefalede daglige dosis lenvatinib hos DTC patienter Dosisniveau 
Table 1 Dose modifications from recommended lenvatinib daily dose in DTC patientsa
Posteriort reversibelt encefalopatisyndrom (PRES)/reversibelt posteriort leukoencefalopatisyndrom (RPLS) (se pkt. 
Posterior reversible encephalopathy syndrome (PRES) / Reversible posterior leucoencephalopathy syndrome (RPLS) (see section 4.4)
Hypomagnesæmi omfatter hypomagnesæmi og et nedsat niveau af magnesium i blodet. 
Hypomagnesaemia includes hypomagnesaemia and decreased blood magnesium.
Reaktioner af grad 3 eller derover (herunder 1 reaktion af grad 4) forekom hos 44,4 % af de lenvatinibbehandlede patienter sammenlignet med 3,8 % af de placebobehandlede patienter. 
Reactions of Grade 3 or higher (including 1 reaction of Grade 4) occurred in 44.4% of lenvatinib-treated patients compared with 3.8% of placebo-treated patients.
Sort jernoxid (E172) Kaliumhydroxid Propylenglycol 
Black iron oxide (E172) Potassium hydroxide Propylene glycol
Brug af anden medicin sammen med LENVIMA Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden medicin eller planlægger at tage anden medicin. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Lenvatinib kan som andre stoffer i den samme klasse påvirke sårhelingsprocessen negativt. 
Lenvatinib may adversely affect the wound healing process as for other agents of the same class.
Der kræves ingen justering af startdosis på basis af nyrefunktionen hos patienter med let eller moderat nedsat nyrefunktion. 
No adjustment of starting dose is required on the basis of renal function in patients with mild or moderate renal impairment.
Alvorlige tumorrelaterede blødninger, herunder dødelige blødningshændelser, er forekommet i kliniske studier og er blevet rapporteret efter markedsføring (se pkt. 
Serious tumour related bleeds, including fatal haemorrhagic events have occurred in clinical trials and have been reported in post-marketing experience (see section 4.8, Description of selected adverse reactions).
Der er ikke udført formelle studier af lenvatinibs indvirkning på sårheling. 
No formal studies of the effect of lenvatinib on wound healing have been conducted.
For patienter som tidligere var normotensive bør der startes monoterapi med et middel fra en af de antihypertensive klasser ved observation af forhøjet blodtryk. 
For previously normotensive subjects, monotherapy with one of the classes of antihypertensives should be started when elevated BP is observed.
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN Eisai GmbH 
Marketing Authorisation Holder Eisai GmbH
Mave-tarm- og abdominalblødning omfatter: abdominalt besvær, abdominalsmerter, smerter i nedre del af abdomen, smerter i øvre del af abdomen, ømhed i abdomen, epigastrisk besvær og mave-tarm-smerter. 
Gastrointestinal and abdominal pain includes: abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, epigastric discomfort, and gastrointestinal pain.
Hepatisk encefalopati omfatter: hepatisk encefalopati, leverkoma, metabolisk encefalopati og encefalopati. 
Hepatic encephalopathy includes: hepatic encephalopathy, coma hepatic, metabolic encephalopathy and encephalopathy.
For toksciteter, der er forbundet med lenvatinib (se tabel 3), kan behandlingen genoptages med en reduceret dosis lenvatinib, som foreslået i tabel 1, når en bivirkning har fortaget sig eller er bedret til grad 0-1 eller baseline. 
For lenvatinib related toxicities (see Table 3), upon resolution/improvement of an adverse reaction to Grade 0-1 or baseline, treatment should be resumed at a reduced dose of lenvatinib as suggested in Table 1.
Behandlingen skal seponeres i tilfælde af livstruende reaktioner (f.eks. grad 4), med undtagelse af laboratorieanomalier, der bedømmes til ikke at være livstruende. 
Treatment should be discontinued in case of life-threatening reactions (e.g., Grade 4) with the exception of laboratory abnormality judged to be non-life-threatening, in which case they should be managed as severe reaction (e.g., Grade 3).
Der er blevet rapporteret om tilfælde af nefrotisk syndrom hos patienter, som fik lenvatinib. 
Cases of nephrotic syndrome have been reported in patients using lenvatinib.
Mave-tarm-perforation og fisteldannelse 
Gastrointestinal perforation and fistula formation
Patienter med nedsat leverfunktion ved baseline havde en større forekomst af hypertension og PPE og en større forekomst af grad 3 eller 4 hypertension, asteni, træthed og hypocalcæmi sammenlignet med patienter med normal leverfunktion. 
Patients with baseline hepatic impairment had a higher incidence of hypertension and PPE, and a higher incidence of Grade 3 or 4 hypertension, asthenia, fatigue, and hypocalcaemia compared with patients with normal hepatic function.
Nogle tilfælde af blødning er opstået sekundært til tumorsvind og fisteldannelse, f.eks. trakeoøsofageale fistler. 
Some cases of bleeding have occurred secondarily to tumour shrinkage and fistula formation, e.g. tracheo-oesophageal fistulae.
Lenvatinib og dets metabolitter udskilles i rottemælk (se pkt. 
Lenvatinib and its metabolites are excreted in rat milk (see section 5.3).
5.1) var der 1 hændelse med PRES (grad 2) i gruppen behandlet med lenvatinib og ingen rapporter i placebogruppen. 
In the pivotal Phase 3 SELECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-treated group and no reports in the placebo group.
Reaktioner af sværhedsgrad 3 eller 4 forekom hos 5,0 % af lenvatinibbehandlede patienter versus 0 placebobehandlede patienter. 
Reactions of Grade 3 or 4 severity occurred in 5.0% of lenvatinibtreated vs 0 placebo-treated patients.
Efter du har drukket den, hælder du den samme mængde vand eller æblejuice i glasset, drejer det rundt og sluger det. 
After drinking, add the same amount of water or apple juice, swirl and swallow.
Tilfælde af nyresvigt omfatter: akut prærenalt svigt, nyresvigt, akut nyresvigt, akut nyreskade og renal tubulær nekrose. 
Renal failure cases includes: acute prerenal failure, renal failure, renal failure acute, acute kidney injury and renal tubular necrosis.
5.1) blev hypertension (inklusive hypertension, øget blodtryk, øget diastolsk blodtryk og ortostatisk hypertension) rapporteret hos 44,5 % af lenvatinib-behandlede patienter og grad 3 hypertension forekom hos 23,5 %. 
In the Phase 3 -REFLECT trial (see section 5.1), hypertension (including hypertension, increased blood pressure, increased diastolic blood pressure and orthostatic hypertension) was reported in 44.5% of lenvatinib-treated patients and Grade 3 hypertension occurred in 23.5%.
Kapselskal Hypromellose Titandioxid (E171) Gul jernoxid (E172) Rød jernoxid (E172) 
Capsule shell Hypromellose Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172)
Hvis du har taget for meget LENVIMA, skal du straks kontakte lægen eller apotekspersonalet. 
If you take more LENVIMA than you should, talk to a doctor or pharmacist straight away.
Lymfopenia 
Lymphopeniaa
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer): 
Uncommon (may affect up to 1 in 100 people)
• kvalme og opkastning, forstoppelse, diarré, mavesmerter, fordøjelsesbesvær 
• feeling sick and being sick, constipation, diarrhoea, abdominal pain, indigestion
Justeret Dosisb (<60 kg kropsvægt) 
Adjusted Doseb (<60 kg BW)
Orale smerter omfatter: orale smerter, glossodyni, smerter i tandkødet, orofaryngeale gener, orofaryngeale smerter og ubehag i tungen. 
Oral pain includes: oral pain, glossodynia, gingival pain, oropharyngeal discomfort, oropharyngeal pain and tongue discomfort.
Kapselskallen indeholder hypromellose, titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172). 
The capsule shell contains hypromellose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
De hyppigst rapporterede bivirkninger (der forekom hos ≥ 30 % af patienterne) er hypertension (68,6 %), diarré (62,8 %), nedsat appetit (51,5 %), vægttab (49,1 %), træthed (45,8 %), kvalme (44,5 %), proteinuri (36,9 %), stomatitis (35,8 %), opkastning (34,5 %), dysfoni (34,1 %), hovedpine (34,1 %) og palmar-plantar erytrodysæstesisyndrom (PPE) (32,7 %). 
The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (68.6%), diarrhoea (62.8%), decreased appetite (51.5%), decreased weight (49.1%), fatigue (45.8%), nausea (44.5%), proteinuria 36.9%), stomatitis (35.8%), vomiting (34.5%), dysphonia (34.1%), headache (34.1%), and palmar-plantar erythrodysaesthesia syndrome (PPE) (32.7%).
Fistel uden for mave-tarm-kanalen omfatter tilfælde af fistler uden for maven og tarmen, såsom trakeal, trakeoøsofageal, øsofageal fistel samt fistel i de kvindelige kønsorganer og kutan fistel. 
Non-gastrointestinal fistula includes cases of fistula occurring outside of the stomach and intestines such as tracheal, tracheo-oesophageal, oesophageal, female genital tract fistula, and cutaneous fistula.
Hos HCC-patienter, der blev behandlet med lenvatinib i REFLECT-undersøgelsen, blev leverrelaterede bivirkninger inklusive hepatisk encefalopati og nedsat leverfunktion (herunder dødelige tilfælde) rapporteret med en højere frekvens (se pkt. 
In HCC patients treated with lenvatinib in the REFLECT trial, liver-related adverse reactions including hepatic encephalopathy and hepatic failure (including fatal reactions) were reported at a higher frequency (see Section 4.8) compared to patients treated with sorafenib .
• udpræget træthed eller svækkelse 
• feeling very tired or weak
5.1) blev hypertension (herunder hypertension, hypertensiv krise, forhøjet diastolisk blodtryk og forhøjet blodtryk) rapporteret hos 72,8 % af de lenvatinibbehandlede patienter og hos 16,0 % af patienterne i gruppen, der fik placebo. 
In the pivotal Phase 3 SELECT trial (see section 5.1), hypertension (including hypertension, hypertensive crisis, increased diastolic blood pressure , and increased blood pressure) was reported in 72.8% of lenvatinib-treated patients and 16.0% of patients in the placebo-treated group.
• hovedpine og rygsmerter 
• headache and back pain
PRES, kaldes også RPLS, er blevet rapporteret hos patienter i behandling med lenvatinib (< 1 %, se pkt. 
PRES, also known as RPLS, has been reported in patients treated with lenvatinib (<1%; see section 4.8, Description of selected adverse reactions).
Prægeblækket indeholder: shellac, sort jernoxid (172), kaliumhydroxid, propylenglycol. 
The printing ink contains shellac, black iron oxide (E172), potassium hydroxide, propylene glycol.
Den mediane tid til start hos lenvatinibbehandlede patienter var 16 dage. 
The median time to onset in lenvatinib-treated patients was 16 days.
• tidligere har haft hjerteproblemer eller slagtilfælde 
• have a history of heart problems or stroke
5.1) blev hypocalcæmi rapporteret hos 1,1 % af patienterne, hvor grad 3 reaktioner forekom hos 0,4 %. 
In the Phase 3 REFLECT trial (see section 5.1), hypocalcaemia was reported in 1.1% of patients, with grade 3 reactions occurring in 0.4%.
Behandling af visse bivirkninger kan kræve dosisafbrydelse, justering eller seponering af lenvatinibbehandlingen. 
Management of some adverse reactions may require dose interruption, adjustment, or discontinuation of lenvatinib therapy.
Trombocytopeni omfatter trombocytopeni og et nedsat antal trombocytter. 
Thrombocytopenia includes thrombocytopenia and decreased platelet count.
Patienter, som har fået 1 tidligere VEGF/VEGFR-målrettet behandling (%) Antal progressioner eller dødsfald Median PFS i måneder (95 % CI) 
Patients who had received 1 prior VEGF/VEGFR-targeted therapy (%) Number of progressions or deaths Median PFS in months (95% CI)
Asiatiske patienter havde en større forekomst end kaukasiske patienter af perifert ødem, hypertension, træthed, PPE, proteinuri, trombocytopeni og forhøjet niveau af tyreoideastimulerende hormon i blodet. 
Asian patients had a higher incidence than Caucasian patients of peripheral oedema, hypertension, fatigue, PPE, proteinuria, thrombocytopenia, and increased blood thyroid stimulating hormone.
Tabel 5 Bivirkninger rapporteret hos patienter i behandling med lenvatinib Systemorganklasse (MedDRAterminologi*) 
Table 5 Adverse reactions reported in patients treated with lenvatinib System Organ
Det anbefales at overvåge den overordnede sikkerhed hos patienter med let til moderat nedsat leversfunktion nøje (se også pkt. 
Close monitoring of the overall safety is recommended in patients with mild or moderate hepatic impairment (see also sections 4.2 and 5.2).
Dosisjustering er ikke nødvendig på basis af nyrefunktion hos patienter med let eller moderat nedsat nyrefunktion. 
No dose adjustments are required on the basis of renal function in patients with mild or moderate renal impairment.
5.1) havde 89,6 % af patienterne et baseline niveau af TSH, der var under den øvre grænse for det normale. 
In the Phase 3 REFLECT trial (see section 5.1), 89.6% of patients had a baseline TSH level of less than the upper limit of normal.
5.1) blev forlængelse af QT/QTc-intervallet rapporteret hos 6,9 % af de lenvatinib-behandlede patienter. 
In the Phase 3 REFLECT trial (see section 5.1), QT/QTc interval prolongation was reported in 6.9% of lenvatinib-treated patients.
På tværs af kliniske studier, i hvilke 1.327 patienter fik lenvatinib som monoterapi til andre indikationer end HCC, blev blødning af grad 3 eller derover rapporteret hos 2 % af patienterne, 3 patienter (0,32 %) havde en grad 4 blødning, og 8 patienter (0,4 %) havde en grad 5 reaktion, herunder arteriel blødning, hjerneblødning, intrakanial blødning, intrakranial tumorblødning, hæmatemese, melæna, hæmoptyse og tumorblødning. 
Across clinical studies in which 1,327 patients received lenvatinib monotherapy in indications other than HCC, Grade ≥ 3 or greater haemorrhage was reported in 2% of patients, 3 patients (0.2%) had a Grade 4 haemorrhage and 8 patients (0.6%) had a Grade 5 reaction including arterial haemorrhage, haemorrhagic stroke, intracranial haemorrhage, intracranial tumour haemorrhage, haematemesis, melaena, haemoptysis and tumour haemorrhage.
Bivirkninger, der mest almindeligt førte til dosisreduktioner (hos ≥ 5 % af patienterne), var hypertension, proteinuri, diarré, træthed, PPE, vægttab og nedsat appetit. 
Adverse reactions that most commonly led to dose reductions (in ≥5% of patients) were hypertension, proteinuria, diarrhoea, fatigue, PPE, decreased weight, and decreased appetite.
Patienter med hypertension ved baseline havde en større forekomst af grad 3 eller 4 hypertension, proteinuri, diarré og dehydrering og oplevede mere alvorlige tilfælde af dehydrering, hypotension, lungeemboli, malign pleuraeffusion, atrieflimmer og mave-tarm-symptomer (abdominalsmerter, diarré, opkastning). 
Patients with baseline hypertension had a higher incidence of Grade 3 or 4 hypertension, proteinuria, diarrhoea, and dehydration, and experienced more serious cases of dehydration, hypotension, pulmonary embolism, malignant pleural effusion, atrial fibrillation, and GI symptoms (abdominal pain, diarrhoea, vomiting).
≥60 kg kropsvægt 12 mg (tre 4 mg kapsler oralt en gang dagligt) 
≥60 kg BW 12 mg (three 4 mg capsules orally once daily)
Arteriel tromboemboli (cerebrovaskulært anfald, transitorisk iskæmisk anfald og myokardieinfarkt) er blevet rapporteret hos patienter i behandling med lenvatinib (se pkt. 
Arterial thromboembolisms (cerebrovascular accident, transient ischaemic attack, and myocardial infarction) have been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
Asiatiske patienter havde en højere forekomst end kaukasiske patienter af proteinuri, nedsat neutrocyttal, nedsat trombocyttal, nedsat antal hvide blodlegemer og PPE syndrom, mens kaukasiske patienter havde en højere forekomst af træthed, hepatisk encefalopati, akut nyreskade, angst, asteni, kvalme, trombocytopeni, og opkastning. 
Asian patients had a higher incidence than Caucasian patients of proteinuria, decreased neutrophil count, decreased platelet count, decreased white blood count and PPE syndrome, while Caucasian patients had a higher incidence of fatigue, hepatic encephalopathy, acute kidney injury, anxiety, asthenia, nausea, thrombocytopenia and vomiting.
Patienter med nedsat nyrefunktion ved baseline havde en højere forekomst af træthed, hypotyreoidisme, dehydrering, diarré, nedsat appetit, proteinuri og hepatisk encefalopati. 
Patients with baseline renal impairment had a higher incidence of fatigue, hypothyroidism, dehydration, diarrhoea, decreased appetite, proteinuria and hepatic encephalopathy.
5.1) blev der rapporteret hjertedysfunktion (inklusive kongestivt hjertesvigt, kardiogent shock og hjerte-lunge-svigt) hos 0,6 % af patienterne (0,4 % var grad ≥ 3) i den lenvatinib-behandlede gruppe. 
In the Phase 3 REFLECT trial (see section 5.1), cardiac dysfunction (including congestive cardiac failure, cardiogenic shock, and cardiopulmonary failure) was reported in 0.6% of patients (0.4% were Grade ≥ 3) in the lenvatinib-treated group.
Nedsat nyrefunktion Forhøjet niveau af kreatinin i blodet Forhøjet niveau af urinstof i blodet 
Renal impairment Increased blood creatinine Increased blood urea
5.1) blev proteinuri rapporteret hos 26,3 % af lenvatinibbehandlede patienter og grad 3 reaktioner forekom hos 5,9 %. 
In the Phase 3 REFLECT trial (see section 5.1), proteinuria was reported in 26.3% of lenvatinibtreated patients and Grade 3 reactions occurred in 5.9%.
5.1) blev blødning rapporteret hos 34,9 % (1,9 % var grad ≥ 3) af de lenvatinibbehandlede patienter versus 18,3 % (3,1 % var grad ≥ 3) af de placebobehandlede patienter. 
In the pivotal Phase 3 SELECT trial (see section 5.1), haemorrhage was reported in 34.9% (1.9% were Grade ≥ 3) of lenvatinib-treated patients versus 18.3% (3.1% were Grade ≥ 3) of placebo-treated patients.
Hvis proteinuri ≥ 2+ detekteres med urinstix, kan det være nødvendigt med dosisafbrydelser, -justeringer eller -seponering (se pkt. 
If urine dipstick proteinuria ≥2+ is detected, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Patienter, som har fået 0 tidligere VEGF/VEGFR-målrettede behandlinger (%) Antal progressioner eller dødsfald Median PFS i måneder (95 % CI) 
Patients who had received 0 prior VEGF/VEGFR-targeted therapy (%) Number of progressions or deaths Median PFS in months (95% CI)
5.1) blev diarré rapporteret hos 38,7 % af patienterne, der blev behandlet med lenvatinib (4,2% var grad ≥ 3). 
In the Phase 3 REFLECT trial (see section 5.1), diarrhoea was reported in 38.7% of patients treated with lenvatinib (4.2% were Grade ≥ 3).
Mave-tarmperforation eller fistel 
GI perforation or fistula
Hos patienter med tegn eller symptomer på PRES kan det være nødvendigt med dosisafbrydelser, -justeringer eller seponering (se pkt. 
In patients with signs or symptoms of PRES, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Hæmning af undertrykkelse af tyreoideastimulerende hormon/tyreoideadysfunktion 
Impairment of thyroid stimulating hormone suppression/ Thyroid dysfunction
Patienter med nedsat nyrefunktion ved baseline havde en større forekomst af grad 3 eller 4 hypertension, proteinuri, træthed, stomatitis, perifert ødem, trombocytopeni, dehydrering, QTforlængelse, hypotyreoidisme, hyponatriæmi, forhøjet niveau af tyreoideastimulerende hormon i blodet, pneumoni sammenlignet med personer med normal nyrefunktion. 
Patients with baseline renal impairment had a higher incidence of Grade 3 or 4 hypertension, proteinuria, fatigue, stomatitis, oedema peripheral, thrombocytopenia, dehydration, prolonged QT, hypothyroidism, hyponatraemia, increased blood thyroid stimulating hormone, pneumonia compared with subjects with normal renal function.
Patienter i alderen ≥ 75 år havde en større tendens til hypertension, proteinuri, nedsat appetit, asteni, dehydrering, svimmelhed, utilpashed, perifert ødem, pruritus og hepatisk encefalopati. 
Patients of age ≥75 years were more likely to experience hypertension, proteinuria, decreased appetite, asthenia, dehydration, dizziness, malaise, peripheral oedema, pruritus and hepatic encephalopathy.
5.1) var der en hændelse med PRES (grad 2) i den lenvatinibbehandlede gruppe. 
In the Phase 3 REFLECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-treated group.
Arteriel tromboemboli (se pkt. 
Arterial thromboembolisms (see section 4.4)
Leverrelaterede reaktioner af grad 3 eller derover (herunder 1 grad 5 tilfælde af leversvigt) forekom hos 5,4 % af de lenvatinibbehandlede patienter sammenlignet med 0,8 % af de placebobehandlede patienter. 
Liver-related reactions of Grade 3 or higher (including 1 Grade 5 case of hepatic failure) occurred in 5.4% of lenvatinib-treated patients compared with 0.8% in placebo-treated patients.
Mave-tarm-perforation og fisteldannelse (se pkt. 
Gastrointestinal perforation and fistula formation (see section 4.4)
Hazard ratio (95 % CI)b, e P-værdib,e 
Hazard ratio (95% CI)b, e P-value b, e
Hazard ratio (99 % CI)b,c P-værdib 
Hazard ratio (99% CI)b,c P-valueb
Hos 496 patienter med HCC var dosisreduktion (afbrydelse eller reduktion) og seponering de udførte handlinger for en bivirkning hos henholdsvis. 
In 496 patients with HCC, dose modification (interruption or reduction) and discontinuation were the actions taken for an adverse reaction in 62.3% and 20.2% of patients, respectively.
De vigtigste alvorlige bivirkninger var nyresvigt og nedsat nyrefunktion (2,4 %), arteriel tromboemboli (3,9 %), hjertesvigt (0,7 %), intrakranial tumorblødning (0,7 %), PRES/RPLS (0,2 %), leversvigt (0,2 %) og arteriel tromboemboli (cerebrovaskulært anfald (1,1 %), transitorisk iskæmisk anfald (0,7 %) og myokardieinfarkt (0,9 %). 
The most important serious adverse reactions were renal failure and impairment (2.4%), arterial thromboembolisms (3.9%), cardiac failure (0.7%), intracranial tumour haemorrhage (0.7%), PRES / RPLS (0.2%), hepatic failure (0.2%), and arterial thromboembolisms (cerebrovascular accident (1.1%), transient ischaemic attack (0.7%), and myocardial infarction (0.9%).